Oxford Drug Design raises £2.2M to develop AI-based drug discovery programme
Biotechnology firm Oxford Drug Design Limited (ODD) has raised £2.2M in funding from existing investors ACF Investors, o2h Ventures, Meltwind Advisory, several returning angels and new investors and the US-based R42 Group.
The Oxford University spinout has created an artificial intelligence (AI) AI proprietary platform...
